论文部分内容阅读
2例患者静脉滴注利妥昔单抗引起过敏反应。例1为61岁女性非霍奇金淋巴瘤患者,为行化疗入院。入院当日给予利妥昔单抗600mg,1次/d静脉滴注。2h后患者出现咽部不适,并伴有气急、畏寒、发热、寒战,T37.8℃。停用利妥昔单抗,给予地塞米松静脉注射,2h后症状缓解。再次给予利妥昔单抗静脉滴注,约半小时后患者出现吞咽困难、气急、大汗淋漓,BP80/52mmHg。再次停用利妥昔单抗,并给于抗过敏治疗,4h后症状好转。例2为52岁女性慢性淋巴细胞白血病患者,因病情进展行氟达拉宾+利妥昔单抗联合化疗。给予利妥昔单抗600mg,1次/d静脉滴注。约半小时后患者出现胸闷、气急、喉咙紧缩感、口唇紫绀,并伴有畏寒、寒战,双肺散在哮鸣音。停用利妥昔单抗,给予吸氧及抗过敏治疗,2h后症状缓解。次日改用环磷酰胺+氟达拉宾联合化疗,未再出现上述症状。
Intravenous drip rituximab in 2 patients caused an allergic reaction. Example 1 A 61-year-old woman with non-Hodgkin’s lymphoma who was admitted for chemotherapy. On the day of admission rituximab 600mg, 1 / d intravenous infusion. 2h after the patient had pharyngeal discomfort, accompanied by shortness of breath, chills, fever, chills, T37.8 ℃. Rituximab was discontinued, and intravenous dexamethasone was given. Symptoms were relieved after 2 hours. Rituximab given intravenously again, about half an hour after patients with dysphagia, shortness of breath, sweating, BP80 / 52mmHg. Rituximab again disabled, and given anti-allergy treatment, 4h after symptoms improved. Example 2 for 52-year-old female patients with chronic lymphocytic leukemia due to progression of fludarabine + rituximab combined with chemotherapy. Given rituximab 600mg, 1 / d intravenous infusion. About half an hour later, the patient developed chest tightness, shortness of breath, tightness of the throat, cyanotic lips, accompanied by chills, chills and wheezing in the lungs. Rituximab discontinued, given oxygen and anti-allergy treatment, 2h after the symptoms were relieved. The next day to cyclophosphamide + fludarabine combined chemotherapy, no recurrence of the above symptoms.